CAL-101,a novel agent of targeted therapy in hematological malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 530-533, 2014.
Article
de Zh
| WPRIM
| ID: wpr-349676
Bibliothèque responsable:
WPRO
ABSTRACT
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pharmacologie
/
Purines
/
Transduction du signal
/
Tumeurs hématologiques
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Quinazolinones
/
Phosphatidylinositol 3-kinase de classe Ia
Limites du sujet:
Animals
/
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2014
Type:
Article